CL2009001010A1 - Uso de una composicion que comprende un antagonista de progesterona para el tratamiento de una condicion dependiente de estrogenos y uso una composicion que comprende un compuesto derivado de progesterona para el tratamiento del dolor asociado con endiometrosis, hemoragia uterina disfuncional, fibroides uterinos y dismenorrea. - Google Patents

Uso de una composicion que comprende un antagonista de progesterona para el tratamiento de una condicion dependiente de estrogenos y uso una composicion que comprende un compuesto derivado de progesterona para el tratamiento del dolor asociado con endiometrosis, hemoragia uterina disfuncional, fibroides uterinos y dismenorrea.

Info

Publication number
CL2009001010A1
CL2009001010A1 CL2009001010A CL2009001010A CL2009001010A1 CL 2009001010 A1 CL2009001010 A1 CL 2009001010A1 CL 2009001010 A CL2009001010 A CL 2009001010A CL 2009001010 A CL2009001010 A CL 2009001010A CL 2009001010 A1 CL2009001010 A1 CL 2009001010A1
Authority
CL
Chile
Prior art keywords
composition
treatment
progesterone
estrogen
endiometrosis
Prior art date
Application number
CL2009001010A
Other languages
English (en)
Spanish (es)
Inventor
Joseph S Podolski
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of CL2009001010A1 publication Critical patent/CL2009001010A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CL2009001010A 2008-04-28 2009-04-28 Uso de una composicion que comprende un antagonista de progesterona para el tratamiento de una condicion dependiente de estrogenos y uso una composicion que comprende un compuesto derivado de progesterona para el tratamiento del dolor asociado con endiometrosis, hemoragia uterina disfuncional, fibroides uterinos y dismenorrea. CL2009001010A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4847208P 2008-04-28 2008-04-28

Publications (1)

Publication Number Publication Date
CL2009001010A1 true CL2009001010A1 (es) 2009-06-19

Family

ID=40751037

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001010A CL2009001010A1 (es) 2008-04-28 2009-04-28 Uso de una composicion que comprende un antagonista de progesterona para el tratamiento de una condicion dependiente de estrogenos y uso una composicion que comprende un compuesto derivado de progesterona para el tratamiento del dolor asociado con endiometrosis, hemoragia uterina disfuncional, fibroides uterinos y dismenorrea.

Country Status (24)

Country Link
US (2) US8426394B2 (https=)
EP (1) EP2293797B1 (https=)
JP (1) JP5791499B2 (https=)
KR (2) KR20110014162A (https=)
CN (2) CN102014923A (https=)
AR (1) AR071516A1 (https=)
AU (1) AU2009241355B2 (https=)
BR (1) BRPI0911563A2 (https=)
CA (1) CA2722753C (https=)
CL (1) CL2009001010A1 (https=)
DK (1) DK2293797T3 (https=)
EA (3) EA201071249A1 (https=)
ES (1) ES2561810T3 (https=)
IL (1) IL208844A0 (https=)
ME (1) ME01123B (https=)
MX (1) MX2010011272A (https=)
MY (1) MY161059A (https=)
NI (1) NI201000183A (https=)
NZ (1) NZ589533A (https=)
SG (1) SG10201408483QA (https=)
TW (1) TWI477276B (https=)
UA (1) UA102849C2 (https=)
WO (1) WO2009134718A1 (https=)
ZA (1) ZA201007529B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
HUP0900487A2 (hu) * 2009-08-05 2011-03-28 Richter Gedeon Nyrt 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
EP2471537A1 (en) 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2872644A1 (en) * 2012-05-31 2013-12-05 Allergan Pharmaceuticals International Limited Formulations and methods for vaginal delivery of antiprogestins
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9545411B2 (en) * 2012-11-02 2017-01-17 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
HU230381B1 (hu) * 2014-02-17 2016-03-29 Richter Gedeon Nyrt Ipari eljárás szteroid intermedier előállítására
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
EP0163696B1 (en) 1983-11-14 1992-11-25 Columbia Laboratories, Inc. Use of a bioadhesive
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5439913A (en) * 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
FI962109A7 (fi) * 1993-11-16 1996-07-15 Schering Ag Kohdun supistumishäiriöiden hoito typpioksidisyntaasin substraatilla j a/tai luovuttajalla tai typpioksidi-inhibiittorilla
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
WO1996023503A1 (de) * 1995-02-02 1996-08-08 Schering Aktiengesellschaft Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
AU710139B2 (en) 1996-05-01 1999-09-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The 21-substituted progesterone derivatives as new antiprogestational agents
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
AU2805397A (en) 1996-08-30 1998-03-19 Population Council, Center For Biomedical Research, The Vaginal application mifepristone
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6172052B1 (en) 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
AU4584901A (en) * 2000-03-17 2001-10-15 Us Gov Health & Human Serv Structural modification of 19-norprogesterone i: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
IN191020B (https=) 2000-03-28 2003-09-13 Dabur Res Foundation
ES2225525T3 (es) 2000-04-03 2005-03-16 Astenjohnson, Inc. Componente de atadura prerizado.
CZ299942B6 (cs) 2000-10-18 2008-12-29 Schering Aktiengesellschaft Farmaceutické prostredky obsahující antiprogestinpro prevenci a lécení hormonálne závislých onemocnení
AU2002318225B2 (en) 2001-07-09 2007-12-13 Repros Therapeutics Inc. Methods and materials for the treatment of testosterone deficiency in men
DE602004026173D1 (de) 2003-04-29 2010-05-06 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
EP1593376A1 (en) 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
US8865200B2 (en) * 2004-07-09 2014-10-21 Laboratoire Hra Pharma Sustained release compositions containing progesterone receptor modulators
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
DE102005028970A1 (de) * 2005-06-22 2006-12-28 Siemens Ag Piezoakter mit gesteigertem Hubvermögen
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
AU2007327707B2 (en) * 2006-10-24 2012-07-12 Allergan pharmaceuticals International Ltd. Compositions and methods for suppressing endometrial proliferation
CA2674440A1 (en) * 2007-01-17 2008-07-24 Repros Therapeutics Inc. Methods for improved stability of steroid derivatives
AU2008237246B2 (en) 2007-04-05 2014-06-05 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
PT2148681E (pt) * 2007-04-20 2016-06-17 Preglem Sa Moduladores seletivos da progesterona no tratamento da hemorragia uterina
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
EP2482914A1 (en) 2009-09-29 2012-08-08 Koninklijke Philips Electronics N.V. Intrauterine electronic capsule for administering a substance

Also Published As

Publication number Publication date
UA102849C2 (ru) 2013-08-27
BRPI0911563A2 (pt) 2016-07-12
AU2009241355B2 (en) 2013-11-14
SG10201408483QA (en) 2015-02-27
ES2561810T3 (es) 2016-03-01
EA201990835A3 (ru) 2019-12-30
EP2293797B1 (en) 2015-11-11
IL208844A0 (en) 2011-01-31
TW200950786A (en) 2009-12-16
US8735381B2 (en) 2014-05-27
EA032646B1 (ru) 2019-06-28
WO2009134718A8 (en) 2010-09-23
JP2011518845A (ja) 2011-06-30
MY161059A (en) 2017-04-14
EP2293797A1 (en) 2011-03-16
AR071516A1 (es) 2010-06-23
EA201990835A2 (ru) 2019-08-30
EA201401347A1 (ru) 2015-07-30
US20130289008A1 (en) 2013-10-31
NZ589533A (en) 2012-06-29
ZA201007529B (en) 2011-07-27
KR20110014162A (ko) 2011-02-10
CN105616427A (zh) 2016-06-01
AU2009241355A1 (en) 2009-11-05
KR20130059442A (ko) 2013-06-05
CA2722753C (en) 2018-07-03
DK2293797T3 (en) 2016-01-11
JP5791499B2 (ja) 2015-10-07
CA2722753A1 (en) 2009-11-05
ME01123B (me) 2013-03-20
US8426394B2 (en) 2013-04-23
US20110046098A1 (en) 2011-02-24
NI201000183A (es) 2012-06-06
WO2009134718A1 (en) 2009-11-05
MX2010011272A (es) 2010-12-21
EA201071249A1 (ru) 2011-08-30
TWI477276B (zh) 2015-03-21
CN102014923A (zh) 2011-04-13

Similar Documents

Publication Publication Date Title
CL2009001010A1 (es) Uso de una composicion que comprende un antagonista de progesterona para el tratamiento de una condicion dependiente de estrogenos y uso una composicion que comprende un compuesto derivado de progesterona para el tratamiento del dolor asociado con endiometrosis, hemoragia uterina disfuncional, fibroides uterinos y dismenorrea.
BRPI0404688B8 (pt) composição para tratamento vaginal, uso da mesma, óvulo de tratamento, creme de tratamento, tampão vaginal para tratamento, e, forro de calcinha para tratamento
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
MX363697B (es) Formulaciones orales de derivados de pirrolidina.
DE60326490D1 (de) Verwendung von gnrh-agonisten zur unterstützung der lutealphase während einer unfruchtbarkeitsbehandlung
AR124479A1 (es) Métodos de monitoreo de la digoxina con el uso de vibegrón para el tratamiento de la vejiga hiperactiva
EA201990106A1 (ru) Режим приема селективного модулятора рецептора прогестерона (sprm)
CN104434135B (zh) 一种隐藏式一次性安全采血针
CN201040004Y (zh) 宫腔压迫止血器
CN204134027U (zh) 一种药物缓释妇科内裤
CN201127314Y (zh) 医用保暖袜
UY29861A1 (es) Uso de valerato de estradiol en combinación con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepcion oral
CN205586037U (zh) 一种捆扎器
CN204501241U (zh) 医用弹力袜助穿装置
Stokoz et al. THE EFFECTIVENESS OF ACUPUNCTURE IN WOMEN WITH INSUFFICIENT LUTEAL PHASE OF THE MENSTRUAL CYCLE DURING PREGNANCY
CN205458818U (zh) 一种新型压舌板
CN201356599Y (zh) 挂钩保洁式止血带
CN201020146Y (zh) 阴道清洁给药器
Bickers Ethinyl estradiol in the treatment of metrorrhagia
CN207575188U (zh) 一次性使用止血带保护套
CN205411423U (zh) 一种上肢石膏固定装置
EA033350B1 (ru) Санитарно-гигиенический материал с фармакологическими свойствами
吳青穎 et al. Fixed Autoimmune Progesterone Dermatitis in a 24 year-old Woman-A Case Report
CN205548640U (zh) 一次性包皮切割吻合器的调节螺杆与加强助力旋钮组件
CN201481489U (zh) 止血带随形衬垫